MedTrace Logo

Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

NCT06192797 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-11-05

No results posted yet for this study

Summary

This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.

Conditions

  • Cholangiocarcinoma Non-resectable

Interventions

PROCEDURE

HAIC

administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.

DRUG

Lenvatinib plus pucotenlimab

lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Ze-yang Ding · Tongji Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-11
Primary Completion
2026-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06192797 on ClinicalTrials.gov